Single Infusion of Zoledronic Acid More Effective in Paget’s Disease
Sep 8, 2005 - 1:08:00 AM, Reviewed by: Dr.
|
|
A head-to-head study published in The New England Journal of Medicine reports that a single infusion of the investigational bisphosphonate, zoledronic acid 5 mg solution, offers superior efficacy, longer period of remission, and faster onset of action compared to the oral bisphosphonate risedronate (Actonel®) in patients with Paget’s disease.
|
By Novartis,
Paget’s disease is the second most prevalent bone disease after osteoporosis. Affecting more than one million people, the chronic bone disorder is marked by the malfunction of the body’s regular bone building process and may result in pain, deformities and fractures.
This pooled analysis of two identical double-blind, active-controlled studies compared a single 15-minute infusion of zoledronic acid 5 mg solution to oral risedronate (30 mg per day for 60 days) in 357 patients with Paget’s disease. At six months, nearly all patients receiving one dose of zoledronic acid 5 mg solution were effectively treated. Specifically, 96 percent of patients treated with zoledronic acid 5 mg solution responded compared to 74 percent of patients who received risedronate (p<0<0<0 
- The New England Journal of Medicine
www.novartis.com
About Paget’s Disease
Paget’s disease of the bone is characterized by a malfunction in the way bone is built up and broken down at the cellular level, which may result in bone pain, osteoarthritis, deformities and fractures. In the normal cycle of bone life, bone breaks down and is replaced by new bone. In Paget’s disease, that cycle is disrupted and bone breaks down too quickly and replacement bone is not normal.
About Zoledronic Acid 5 mg Solution
The New Drug Application for zoledronic acid 5 mg solution is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of Paget’s disease. The US Food and Drug Administration issued an “approvable letter” for this product for the treatment of Paget’s disease of the bone in March 2005. Novartis is working with the US regulatory agency to gain approval for this indication. Zoledronic acid 5 mg solution received approval for the treatment of Paget’s disease in 27 European countries in April 2005 and in Canada in June 2005. In addition, it is being studied worldwide to evaluate its impact on several other bone disorders including osteoporosis, corticosteroid-induced osteoporosis and osteogenesis imperfecta in children.
The foregoing release contains forward-looking statements that can be identified by terminology such as “may,” “is being studied,” or similar expressions, or by discussions regarding potential regulatory approvals for zoledronic acid, potential new indications for zoledronic acid, or regarding potential future sales of zoledronic acid. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results with zoledronic acid to be materially different from any future results, performance or achievements expressed or implied by such statements. There is no guarantee that zoledronic acid 5 mg solution will be approved by the U.S. Food and Drug Administration or any other regulatory authority for any indication in any market. Neither can there be any guarantee regarding potential future sales of zoledronic acid. In particular, management's ability to ensure satisfaction of any health authorities' requirements is not guaranteed and management's expectations regarding commercialization of zoledronic acid 5 mg solution could be affected by, among other things, additional analysis of zoledronic clinical data; new clinical data; unexpected clinical trial results; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the Securities and Exchange Commission of the United States. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including central nervous system disorders, organ transplantation, cardiovascular diseases, dermatological diseases, respiratory disorders, cancer and arthritis. The company's mission is to improve people's lives by pioneering novel healthcare solutions.
Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG. Novartis AG (NYSE: NVS) is a world leader in pharmaceuticals and consumer health. In 2004, the Group's businesses achieved sales of USD 28.2 billion and a net income of USD 5.8 billion. The Group invested approximately USD 4.2 billion in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 81,400 people and operate in over 140 countries around the world. For further information, please consult http://www.novartis.com.
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
